CGAS and neoplasm: cGAMP produced by constitutively active cGAS in tumor cells can trigger CD11b+ immune cells within the TME resulting in NK cell-dependent tumor rejection [125], and also stimulate STING-dependent type I IFN production in DCs and macrophages [126] (Figure 2).